Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibitionGabrielle S. Wong, Adam J. Bass, Kenichi Nakamura et al.|Nature Medicine|2018Cited by 282
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancerJenny Y. Xue, Piro Lito, Luciano G. Martelotto et al.|Nature Medicine|2017Cited by 181
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric CancerFrancisco Sánchez-Vega, Yelena Y. Janjigian, Jaclyn F. Hechtman et al.|Cancer Discovery|2018Cited by 147
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.Weimin Li, Robert L. Ferris, Sophie Wildsmith et al.|Journal of Clinical Oncology|2020Cited by 27
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibitionGabrielle S. Wong, Adam J. Bass, Jin Zhou et al.|Nature Medicine|2018Cited by 10